King Luther Capital Management Corp reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 39.0% in the third quarter, Holdings Channel reports. The firm owned 17,172 shares of the company’s stock after selling 10,999 shares during the period. King Luther Capital Management Corp’s holdings in Novo Nordisk A/S were worth $2,045,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in the stock. 1620 Investment Advisors Inc. purchased a new stake in Novo Nordisk A/S in the 2nd quarter valued at about $25,000. Gilliland Jeter Wealth Management LLC increased its position in shares of Novo Nordisk A/S by 200.0% during the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after acquiring an additional 120 shares during the period. Strategic Investment Solutions Inc. IL bought a new stake in shares of Novo Nordisk A/S during the second quarter valued at approximately $25,000. Halpern Financial Inc. boosted its holdings in shares of Novo Nordisk A/S by 113.0% in the second quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock valued at $30,000 after purchasing an additional 113 shares during the period. Finally, Abound Wealth Management grew its stake in Novo Nordisk A/S by 257.4% in the second quarter. Abound Wealth Management now owns 218 shares of the company’s stock worth $31,000 after purchasing an additional 157 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.
Novo Nordisk A/S Stock Performance
NVO stock opened at $105.07 on Friday. Novo Nordisk A/S has a one year low of $94.73 and a one year high of $148.15. The firm has a market cap of $471.50 billion, a price-to-earnings ratio of 34.00, a PEG ratio of 1.32 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The firm has a 50-day simple moving average of $115.48 and a two-hundred day simple moving average of $128.79.
Analyst Ratings Changes
Check Out Our Latest Analysis on Novo Nordisk A/S
Novo Nordisk A/S Profile
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Featured Articles
- Five stocks we like better than Novo Nordisk A/S
- 3 Warren Buffett Stocks to Buy Now
- Tesla Investors Continue to Profit From the Trump Trade
- The Risks of Owning Bonds
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- 3 Tickers Leading a Meme Stock Revival
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.